北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2023 年年度股东大会的 法 律 意 见 书 兰台意（2024）第 1764 号 地址：北京市朝阳区曙光西里甲 1 号第三置业大厦 B 座 29 层 电话：（8610）52287799 传真：（8610）58220039 网址：www.lantai.cn 法律意见书 北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2023 年年度股东大会的 法 律 意 见 书 兰台意（2024）第 1764 号 致：黑龙江珍宝岛药业股份有限公司 北京市兰台律师事务所（以下简称"本所"）接受黑龙江珍宝岛药业股份有 限公司（以下简称"公司"）的委托，指派本所律师列席公司于 2024 年 5 月 20 日召开的 2023 年年度股东大会（以下简称"本次股东大会"或"会议"）。现 依据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司股东大 会规则》（以下简称"《股东大会规则》"）等法律、行政法规、规范性文件及 《黑龙江珍宝岛药业股份有限公司章程》（以下简称"《公司章程》"）的规定， 本所律师就本次股东大会的相关事项进行见证并出具本法律意见书。 对于出具本法 ...

黑龙江珍宝岛药业股份有限公司 2023 年年度股东大会决议公告 证券代码：603567 证券简称：珍宝岛 公告编号：2024-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 9 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 515,926,705 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 54.7794 | | 份总数的比例（%） | | 注：公司总股本为 941,963,592 股，公司回购专户持股数量为 137,232 股，回购专户中的股 份不具有表决权。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由董事会召集，公司董事长方同华先生主持。本次会议以现场 和网络投票相结合的方式对股东大会通知中列明的事项进行了投票表决，表决方 式符 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●被担保人名称：哈尔滨珍宝制药有限公司（以下简称"哈珍宝"），系黑龙 江珍宝岛药业股份有限公司（以下简称"公司"）的全资子公司。 ●本次担保金额为人民币 1.70 亿元，截至公告披露日，公司已实际为哈珍 宝提供的担保余额为人民币 6.07 亿元（含本次担保）。 ●截至本公告披露日，公司实际对外担保总额人民币 12.92 亿元（含本次担 保），全部是公司对全资子公司进行的担保。 证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-030 黑龙江珍宝岛药业股份有限公司 关于为全资子公司提供担保的公告 ●本次担保无反担保。 ●公司无对外担保逾期的情况。 一、担保情况概述 （一）担保基本情况 为满足公司全资子公司哈珍宝的银行融资需要，公司于 2024 年 5 月 15 日与 哈尔滨联合农村商业银行股份有限公司呼兰支行签订《保证合同》，公司为哈珍 宝的银行融资提供人民币 1.7 亿元连带责任保证担保，担保期限 12 个月，担保 范围包括"主债权本金、利息 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's performance is expected to grow steadily due to its diversified product matrix and the volume expansion from centralized procurement [2] - The company's industrial revenue increased by 84.79% YoY in 2023, with the industrial segment's gross margin rising by 3.14 percentage points to 64.37% [2] - The company's traditional Chinese medicine (TCM) and chemical drug segments performed well, with TCM revenue increasing by 84.06% YoY and chemical drug revenue increasing by 51.41% YoY in 2023 [2] - The company's commercial and medicinal material sales revenue decreased by 64.6% YoY in 2023, with a slight increase in gross margin by 0.17 percentage points to 3.51% [2] - The company's net profit attributable to the parent company in 2023 was 473 million yuan, a 155% increase YoY, while the non-GAAP net profit attributable to the parent company was a loss of 31.84 million yuan [2] - The company's Q1 2024 revenue was 1.118 billion yuan, a 27.10% decrease YoY, while the net profit attributable to the parent company increased by 15.43% YoY to 293 million yuan [2] Product Portfolio and Market Strategy - The company has 160 production approvals and 129 product varieties, including 82 medical insurance varieties, 31 essential drug varieties, and 3 TCM protected varieties [3] - The company has 4 exclusive varieties, including Fufang Qinlan Oral Liquid and Xueshuantong Capsule, which are expected to drive future growth [3] - The company's Xueshuantong Capsule was selected in the "3+N" centralized procurement in the Beijing-Tianjin-Hebei region, with expected sales growth in 2024 [3] - The company has strategically focused on TCM trade, establishing 16 regional offices and 4 planting bases, enhancing its competitive advantage [3] Financial Projections - The company's net profit attributable to the parent company is projected to be 818 million yuan in 2024, 1.041 billion yuan in 2025, and 1.312 billion yuan in 2026, with YoY growth rates of 73%, 27%, and 26%, respectively [3] - The company's EPS is expected to be 0.87 yuan in 2024, 1.11 yuan in 2025, and 1.39 yuan in 2026, with corresponding P/E ratios of 14X, 11X, and 9X [3] Financial Performance - The company's revenue in 2023 was 3.144 billion yuan, a 25.5% decrease YoY, while the net profit attributable to the parent company increased by 154.9% YoY to 473 million yuan [4] - The company's gross margin improved significantly to 42.4% in 2023, compared to 17.7% in 2022 [7] - The company's ROE increased to 5.8% in 2023 from 2.7% in 2022, with further improvement expected to 12.2% by 2026 [7]

黑龙江珍宝岛药业股份有限公司 2023 年年度股东大会 会 议 资 料 2024.05.20 1 | | 2023 年年度股东大会会议须知 | 3 | | --- | --- | --- | | | 2023 年年度股东大会会议议程 | 4 | | 议案 | 1：2023 | 年度董事会工作报告 6 | | 议案 | 2：2023 | 年度监事会工作报告 6 | | 议案 | 3：2023 | 年度财务决算报告 7 | | 议案 | 4：2024 | 年度财务预算报告 7 | | 议案 | 5：2023 | 年年度报告全文及摘要 8 | | 议案 | 6：2023 | 年度利润分配预案 9 | | 议案 | 7：关于 2024 | 年向金融机构申请授信额度及融资的议案 10 | | 议案 | 8：关于 2024 | 年为子公司提供担保额度的议案 11 | | 议案 | 9：关于续聘公司 | 2024 年度审计机构的议案 12 | | 议案 | | 10：关于董事、高级管理人员 2023 年度薪酬情况及 2024 年度薪酬方案的议案 13 | | 议案 | 11：关于监事 | 2023 年度薪酬情况及 2024 ...

证券代码：603567 证券简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 投资者关系活动记录表 编号：2024-001 □特定对象调研□分析师会议□媒体采访□业绩说明会 投资者关系活 □新闻发布会□路演活动□现场参观 动类别 其他（线上电话交流会） 时 间 2024年5月5日 19:30-20:30（北京时间） 参与单位名称 中药行业证券分析师及投资机构，共计 36 家，机构名单见附 人员姓名 件。 方 式 电话会议 董事长：方同华先生 上市公司接待人 财务总监：王磊先生 员姓名 董事会秘书：张钟方女士 销售公司副总：胡彩龙先生 投资者关系活动 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-029 黑龙江珍宝岛药业股份有限公司 关于召开 2023 年度及 2024 年第一季度业绩 会议召开时间：2024 年 5 月 14 日（星期二）下午 16:00-17:00 1 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 5 月 14 日中午 12:00 前，将关注的问题以电子邮件 的形式发送至黑龙江珍宝岛药业股份有限公司（以下简称"公司"）董事会办公 室邮箱（zbddsh@zbdzy.com），公司将结合实际情况，在信息披露允许的范围内， 就投资者普遍关注的问题在说明会上进行回复。 公司于 2024 年 4 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了 《黑龙江珍宝岛药业股份有限公司 2023 年年度报告》全文及摘要与《黑龙江珍 宝岛药业股份有限公司 2024 年第一季度报告》，为便于广大投资者更全面深入 地了解公司财务状况与经营情况，公司将于 2024 年 5 月 14 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-028 黑龙江珍宝岛药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到国家药品监督管理 局核准签发的左乙拉西坦注射用浓溶液《药品注册证书》（证书编号：2024S00676）， 现就相关情况公告如下： 一、药品的基本情况 药品名称：左乙拉西坦注射用浓溶液 剂型：注射剂 规格：5ml：500mg 注册分类：化学药品 4 类 上市许可持有人：黑龙江珍宝岛药业股份有限公司 生产企业：黑龙江珍宝岛药业股份有限公司 药品批准文号：国药准字 H20243584 药品批准文号有效期：至 2029 年 04 月 23 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药 品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工 艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、药品的其他情况 药品注册标准编号 ...

Financial Performance - The company's operating revenue for 2023 was ¥3,138,186,554.27, a decrease of 25.53% compared to ¥4,214,148,859.72 in 2022[22]. - Net profit attributable to shareholders increased by 154.93% to ¥472,740,021.12 in 2023 from ¥185,440,370.42 in 2022[22]. - The net cash flow from operating activities was -¥478,244,805.78, a decline of 46.34% compared to -¥326,792,760.53 in 2022[22]. - Basic earnings per share rose by 155.43% to ¥0.5032 in 2023 from ¥0.1970 in 2022[29]. - The weighted average return on net assets increased by 3.84 percentage points to 6.4564% in 2023 from 2.6198% in 2022[29]. - The total assets at the end of 2023 were ¥12,465,874,627.30, reflecting a 6.75% increase from ¥11,677,768,228.80 at the end of 2022[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses improved significantly, with a reduction in losses to -¥31,842,460.08 in 2023 from -¥280,408,320.73 in 2022, an improvement of 88.64%[22]. - The company achieved a comprehensive revenue growth rate of -4.0% and a profit growth rate of -16.2% during the reporting period[61]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares, totaling approximately 188.35 million CNY, which represents 39.84% of the net profit attributable to ordinary shareholders[5]. - The total share capital as of December 31, 2023, is 941,963,592 shares, with 941,689,128 shares eligible for the dividend distribution after accounting for treasury shares[5]. - The company has not proposed any stock dividends or capital reserve transfers in this profit distribution plan[5]. Audit and Compliance - The company has received a standard unqualified audit report from Zhongzhun Accounting Firm, ensuring the accuracy and completeness of the financial report[4]. - There are no significant risks that could materially affect the company's operations during the reporting period[7]. - The company has confirmed the absence of non-operational fund occupation by controlling shareholders and related parties[6]. - The company has not violated decision-making procedures regarding external guarantees[6]. - The company is committed to maintaining internal control and has provided detailed information in the internal control audit report[9]. Market and Product Development - The company is focusing on a strategic development plan centered around "two centers, three parks, and four platforms," aiming to enhance the entire industry chain of traditional Chinese medicine[42]. - The company emphasizes market development and customer-centric service operations to drive product volume and improve market access[43]. - The company is committed to strict GMP production management, optimizing production capacity and product structure, and enhancing production cost control[44]. - The company is actively participating in the national centralized procurement policy, which aims to expand the range of drugs included in procurement[64]. - The company is expanding its product line through mergers and acquisitions and innovation in research and development[66]. - The company is pursuing new product launches and expanding into new channels and terminals to foster business growth[74]. Research and Development - The company has 4 innovative drug projects and 39 generic drug projects under development, with a positive trend of new product applications and approvals each year[121]. - The innovative drug ZBD1006, a second-generation FGFR inhibitor, is currently in the Phase I clinical trial stage and is expected to treat multiple types of cancer[121]. - The company is focusing on five major R&D areas, including traditional Chinese medicine and chemical drug mergers, to enhance product clusters in cardiovascular, respiratory, and immune systems[188]. - The company has established a comprehensive R&D incubation park covering traditional Chinese medicine, chemical drugs, and biological drugs to support the pharmaceutical industry's technical needs[193]. Sales and Marketing - The company has developed a comprehensive marketing network covering the entire country, aiming to enhance sales and service efficiency[74]. - The company maintains a diverse marketing strategy, utilizing a combination of different product types and channels to enhance brand value and economic returns, supported by a strong marketing service team and extensive distribution network[104]. - The company emphasizes precise market positioning and segmentation, continuously optimizing marketing strategies to expand product coverage and drive sales growth[106]. - The company is committed to enhancing brand influence through academic promotion and marketing activities, establishing a unified operational standard for brand academic services to increase brand visibility[107]. Financial Position and Cash Flow - The net cash flow from financing activities was 765,692,370.02 CNY, an increase of 282.77% year-on-year[160]. - Cash and cash equivalents at the end of the period amounted to 1,454,040,157.07 CNY, representing 11.66% of total assets, up 45.20% from the previous period[163]. - The company's long-term borrowings increased to 1,298,000,000.00 CNY, a rise of 182.17% compared to the previous period[163]. Industry Trends - The pharmaceutical industry in 2023 saw a revenue decline of 4% and a profit decrease of 16.2%, while traditional Chinese medicine sectors experienced positive growth[53]. - National health expenditure reached 8.5327 trillion yuan in 2022, with a per capita expenditure of 6,044 yuan, reflecting an 11% year-on-year increase[55]. - The total number of medical visits in 2023 was 9.56 billion, representing a 13.5% increase compared to 2022[55]. - The government continues to release supportive policies for the development of traditional Chinese medicine, indicating a strong commitment to the industry's growth[56].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,117,297,002.98, representing a decrease of 27.09% compared to the same period last year[4] - Net profit attributable to shareholders of the listed company was CNY 293,365,824.90, an increase of 15.43% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 281,649,753.39, up 18.23% from the previous year[4] - Basic earnings per share were CNY 0.3123, an increase of 15.75% year-on-year[4] - Diluted earnings per share were CNY 0.3118, also up 15.55% compared to the same period last year[4] - The weighted average return on equity was 3.81%, an increase of 0.29 percentage points year-on-year[4] - The net profit for the current period is 293,272,864.09, an increase from 254,567,799.24 in the previous period, representing a growth of approximately 15.2%[50] - The total profit for the current period is 364,262,078.51, compared to 299,979,137.44 in the previous period, indicating an increase of about 21.4%[50] - The basic earnings per share (EPS) for the current period is 0.3123, up from 0.2698 in the previous period, reflecting a growth of approximately 15.7%[51] - The diluted EPS for the current period is 0.3118, also an increase from 0.2698 in the previous period, showing a growth of around 15.6%[51] Cash Flow - The net cash flow from operating activities was negative at CNY -103,296,907.81, reflecting an increase in outflow of 32.61% compared to last year[4] - In Q1 2024, the cash inflow from operating activities was CNY 451,288,232.60, a decrease of 64.0% compared to CNY 1,254,861,762.57 in Q1 2023[31] - The cash outflow from operating activities totaled CNY 554,585,140.41, down 60.7% from CNY 1,408,139,619.12 in the previous year[32] - The net cash flow from operating activities was negative at CNY -103,296,907.81, an improvement from CNY -153,277,856.55 in Q1 2023[32] - Cash inflow from financing activities was CNY 551,893,257.89, down 54.2% from CNY 1,205,000,000.00 in the previous year[32] - The company received CNY 550,000,000.00 in borrowings, a decrease from CNY 1,205,000,000.00 in Q1 2023[32] - The net cash flow from financing activities is 63,436,562.37, a significant improvement compared to -23,036,839.47 in the previous period[55] - The ending cash and cash equivalents balance is 1,365,772,528.81, up from 824,842,855.30 in the previous period, indicating a growth of approximately 65.5%[55] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 12,880,364,470.24, a 3.32% increase from the end of the previous year[15] - Current assets totaled CNY 7,626,089,907.84, an increase of 6.4% from CNY 7,167,666,681.72 in the previous year[45] - Total liabilities amounted to CNY 4,546,366,012.75, an increase of 2.7% from CNY 4,425,219,914.44 in the previous year[45] - Total assets reached CNY 12,880,364,470.24, up from CNY 12,465,874,627.30, reflecting a growth of 3.3%[46] - Long-term investments increased to CNY 701,280,660.73, up from CNY 673,412,423.69, representing a growth of 4.0%[45] Expenses - Operating costs for Q1 2024 were CNY 680,916,308.96, down 44.4% from CNY 1,225,023,970.30 in Q1 2023[48] - Research and development expenses for Q1 2024 were CNY 3,957,691.13, a decrease of 71.8% compared to CNY 14,040,635.04 in Q1 2023[48] - The company reported a decrease in sales expenses to CNY 99,640,998.01, down 60.2% from CNY 250,719,922.47 in Q1 2023[48] Shareholder Information - The total number of common shareholders at the end of the reporting period was 24,767[38] - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 50.00% of the shares[38] Other Income - The company reported non-operating income of CNY 13,018,283.66 from government subsidies related to normal business operations[35] - The company reported a fair value change gain of 71,171.66, contrasting with a loss of -25,254.46 in the previous period[50] - The company experienced credit impairment losses of -59,080,434.20, which is a decrease from -30,166,769.26 in the previous period, indicating an improvement in credit quality[50]